Peroxisome proliferator-activated receptor-γ polymorphism, body mass and prostate cancer risk: Evidence for gene-environment interaction

Oncology

Volumn 70, Issue 3, 2006, Pages 185-189

  Zmuda, Joseph M ^a,b   Modugno, Francesmary ^a,b   Weissfeld, Joel L ^a,b   Cauley, Jane A ^a   Trump, Donald L ^c   Moffett, Susan P ^a   Ferrell, Robert E ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Genetics; Obesity; Polymorphism; PPAR ; Prostate cancer

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; BODY MASS; CANCER PATIENT; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGED; ALANINE; BODY MASS INDEX; CASE-CONTROL STUDIES; GENOTYPE; HUMANS; INSULIN; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; PPAR GAMMA; PREDICTIVE VALUE OF TESTS; PROLINE; PROSTATIC NEOPLASMS; WAIST-HIP RATIO;

EID: 33746610120     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093805     Document Type: Article

References (27)

1. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-688.
2. Auwerx J: PPARγ, the ultimate thrifty gene. Diabetologia 1999;42:1033-1049.
3. Debril MB, Renaud JP, Fajas L, Auwerx J: The pleiotropic functions of peroxisome proliferator-activated receptor 3. J Mol Med 2001;79:30-47.
4. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 2000;405:421-424.
5. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000;97:10990-10995.
6. Nwankwo JO, Robbins ME: Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot Essent Fatty Acids 2001;64:241-245.
7. Ikezoe T, Miller CW, Kawano S, Heaney A, Williamson EA, Hisatake J, Green E, Hofmann W, Taguchi H, Koeffler HP: Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res 2001;61:5307-5310.
8. Butler R, Mitchell SH, Tindall DJ, Young CY: Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ 2000;11:49-61.
9. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR, Dubois RN: 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor γ and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001;61:497-503.
10. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-3352.
11. Segawa Y, Yoshimura R, Hase T, Nakatani T, Wada S, Kawahito Y, Kishimoto T, Sano H: Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 2002;51:108-116.
12. 12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997;241:270-274.
13. Glynn NW, Meilahn EN, Charron M, Anderson SJ, Kuller LH, Cauley JA: Determinants of bone mineral density in older men. J Bone Miner Res 1995;10:1769-1777.
14. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
15. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer Statistics, 2003. CA Cancer J Clin 2003;53:5-26.
16. 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
17. Nomura A: Body size and prostate cancer. Epidemiol Rev 2001;23:126-131.
18. Hsing AW, Chua S Jr, Gao YT, Gentzschein E, Chang L, Deng J, Stanczyk FZ: Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001;93:783-789.
19. Hsing AW, Gao YT, Chua S Jr, Deng J, Stanczyk FZ: Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003;95:67-71.
20. Polychronakos C, Janthly U, Lehoux JG, Koutsilieris M: Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. Prostate 1991;19:313-321.
21. 12Ala polymorphism. Diabetes 2002;51:2341-2347.
22. 12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
23. 2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 1999;42:758-762.
24. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998;339:953-959.
25. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S: Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880-883.
26. Evans D, Mann WA, Heer J, Michel U, Wendt D, Kortner B, Wolf A, Beisiegel U: Variation in the gene for human peroxisome proliferator activated receptor gamma (PPARγ) does not play a major role in the development of morbid obesity. Int J Obes Relat Metab Disord 2000; 24:647-651.
27. 12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study. Cancer Lett 2003;191:67-74.